Galecto, Inc. GLTO
We take great care to ensure that the data presented and summarized in this overview for Galecto, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GLTO
View allLatest Institutional Activity in GLTO
Top Purchases
Top Sells
About GLTO
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Insider Transactions at GLTO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 03
2025
|
Hans T. Schambye Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,341
-28.3%
|
$6,705
$5.6 P/Share
|
|
Jan 03
2025
|
Hans T. Schambye Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,640
+35.78%
|
-
|
|
Jan 03
2025
|
Lori Firmani Interim CFO |
SELL
Open market or private sale
|
Direct |
261
-35.95%
|
$1,305
$5.63 P/Share
|
|
Jan 03
2025
|
Lori Firmani Interim CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
726
+50.0%
|
-
|
|
Jan 03
2025
|
Garrett Winslow General Counsel |
SELL
Open market or private sale
|
Direct |
471
-31.82%
|
$2,355
$5.6 P/Share
|
|
Jan 03
2025
|
Garrett Winslow General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,320
+47.14%
|
-
|
|
Aug 15
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
822,680
-27.58%
|
$0
$0.75 P/Share
|
|
Jul 31
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
209,400
-8.82%
|
$628,200
$3.0 P/Share
|
|
Jul 25
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
39,200
-2.09%
|
$78,400
$2.92 P/Share
|
|
Jul 13
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
194,700
-5.46%
|
$389,400
$2.4 P/Share
|
|
Apr 17
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
13,089
-0.37%
|
$13,089
$1.97 P/Share
|
|
Apr 14
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
41,446
-1.15%
|
$41,446
$1.86 P/Share
|
|
Apr 13
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
13,946
-0.38%
|
$13,946
$1.82 P/Share
|
|
Apr 12
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,363
-0.06%
|
$2,363
$1.81 P/Share
|
|
Apr 11
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
13,946
-0.38%
|
$13,946
$1.82 P/Share
|
|
Apr 10
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
51,228
-1.37%
|
$51,228
$1.79 P/Share
|
|
Apr 06
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
9,665
-0.26%
|
$19,330
$2.0 P/Share
|
|
Apr 05
2023
|
Orbimed Advisors LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
92,965
-2.44%
|
$185,930
$2.18 P/Share
|
|
Mar 22
2022
|
Hans T. Schambye Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+8.71%
|
$10,000
$2.15 P/Share
|
|
Mar 22
2022
|
Bertil Lindmark Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
14,604
+46.8%
|
$29,208
$2.16 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 4.69K shares |
|---|
| Open market or private sale | 2.07K shares |
|---|